Download Dosing regimens of selective serotonin reuptake inhibitors (SSRIs

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project

Document related concepts

Pharmacokinetics wikipedia, lookup

Neuropharmacology wikipedia, lookup

Theralizumab wikipedia, lookup

Neuropsychopharmacology wikipedia, lookup

Bilastine wikipedia, lookup

Pharmacogenomics wikipedia, lookup

Discovery and development of ACE inhibitors wikipedia, lookup

Psychopharmacology wikipedia, lookup

Discovery and development of neuraminidase inhibitors wikipedia, lookup

Hormesis wikipedia, lookup

Psychedelic therapy wikipedia, lookup

Stimulant wikipedia, lookup

Fluoxetine wikipedia, lookup

Serotonin syndrome wikipedia, lookup

Metalloprotease inhibitor wikipedia, lookup

Transcript
Dosing regimens of selective serotonin reuptake
inhibitors (SSRIs) for anxiety disorders (Table 8.1)*
Drug
Initial daily dose†
Maximum daily dose
citalopram
10 mg
40 mg
escitalopram
5 mg
20 mg
fluoxetine
10 mg
80 mg
fluvoxamine
50 mg
300 mg‡
paroxetine
10 mg
60 mg
sertraline
25 mg
200 mg
* Not every SSRI has Australian TGA approval for use for each anxiety disorder; however, there is insufficient evidence to differentiate between
efficacy of the individual SSRIs.
† Dose orally in the morning after food. Increase dose according to tolerability and patient response.
‡ Doses above 150 mg daily may be given in 2 divided doses for better tolerability.
Therapeutic Guidelines Limited (www.tg.org.au) is an independent not-for-profit organisation dedicated to deriving guidelines for therapy from the latest world literature, interpreted
and distilled by Australia’s most eminent and respected experts.
Reproduced with permission from Psychotropic Expert Group. Dosing regimens of selective serotonin reuptake inhibitors (SSRIs) for anxiety disorders (Table 8.1) [revised 2013].
In: eTG complete [Internet]. Melbourne: Therapeutic Guidelines Limited; 2013.